Helius Medical Technologies, Inc. Share Price Toronto S.E.

Equities

HSM

US42328V1089

Advanced Medical Equipment & Technology

Delayed Toronto S.E. 5-day change 1st Jan Change
- CAD -.--% Intraday chart for Helius Medical Technologies, Inc. +4.21% -.--%

Financials

Sales 2024 * 977K 1.34M 77.89M Sales 2025 * 5.72M 7.82M 456M Capitalization 7.72M 10.56M 615M
Net income 2024 * -11M -15.05M -877M Net income 2025 * -9M -12.31M -717M EV / Sales 2024 * 7.9 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.35 x
P/E ratio 2024 *
-0.27 x
P/E ratio 2025 *
-0.65 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.15%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 58 03/08/17
Director of Finance/CFO 63 08/06/20
Chief Tech/Sci/R&D Officer 57 07/07/21
Members of the board TitleAgeSince
Director/Board Member 85 17/11/14
Chief Executive Officer 58 03/08/17
Chairman 53 28/12/15
More insiders
Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.87 USD
Average target price
15.47 USD
Spread / Average Target
+438.91%
Consensus